U.S. Markets closed

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Ophthotech Corporation to Contact the Firm Before Imminent Lead Plaintiff Deadline

NEW YORK, NY / ACCESSWIRE / March 3, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ophthotech Corporation ("Ophthotech" or the "Company") (OPHT) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Ophthotech common stock or options between May 11, 2015 and December 12, 2016 (the "Class Period"). The case, Micholle v. Ophthotech Corporation et al, No. 17-cv-00210, was filed on January 11, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the effectiveness and potential of its anti-PDGF therapy, Fovista.

Specifically, on December 12, 2016, Ophthotech announced results of the two pivotal phase 3 trials of Fovista, disclosing that the treatment, administered in combination with Lucentis, had failed to achieve its primary endpoint of visual acuity at 12 months, compared to Lucentis administered as a monotherapy under the guidelines established by the FDA.

After the announcement, Ophthotech's share price fell from $38.77 per share on December 9, 2016 to a closing price of $5.29 on December 12, 2015 - a $33.50 or a 86.4% drop.

Request more information now by clicking here: www.faruqilaw.com/OPHT. There is no cost or obligation to you.

Take Action

If you invested in Ophthotech common stock or options between May 11, 2015 and December 12, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/OPHT. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Ophthotech's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

SOURCE: Faruqi & Faruqi, LLP